SAB Biotherapeutics, Inc. (SABS)
NASDAQ: SABS · Real-Time Price · USD
2.900
+0.020 (0.69%)
At close: Oct 8, 2026, 4:00 PM EDT
2.890
-0.010 (-0.34%)
After-hours: Oct 8, 2026, 7:30 PM EDT
SAB Biotherapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
86
Market Cap
262.95M
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | 1.32M | -916.58K | -40.94% |
| Dec 31, 2023 | 2.24M | -21.67M | -90.63% |
| Dec 31, 2022 | 23.90M | -36.97M | -60.73% |
| Dec 31, 2021 | 60.88M | 5.64M | 10.21% |
| Dec 31, 2020 | 55.24M | 51.80M | 1,504.91% |
| Dec 31, 2019 | 3.44M | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Vanda Pharmaceuticals | 215.72M |
| Fulcrum Therapeutics | 80.00M |
| Clinuvel Pharmaceuticals | 65.05M |
| Bicycle Therapeutics | 61.21M |
| Abeona Therapeutics | 25.52M |
| X4 Pharmaceuticals | 15.85M |
| Fate Therapeutics | 6.49M |
| EyePoint | 2.79M |
SABS News
- 7 days ago - SAB BIO to Present SAB-142 Data at the Inaugural Breakthrough T1D Clinical & Research Congress - GlobeNewsWire
- 8 days ago - SAB Biotherapeutics Slides: Corporate presentation - Filings
- 16 days ago - SAB BIO to Present SAB-142 Data at the 62nd Annual Meeting of the European Association for the Study of Diabetes - GlobeNewsWire
- 4 weeks ago - SAB Biotherapeutics Transcript: Citigroup’s Biopharma Back to School Summit 2026 - Transcripts
- 4 weeks ago - SAB Biotherapeutics Slides: FY 2026 - Filings
- 5 weeks ago - SAB BIO to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - SAB Biotherapeutics Earnings Call Transcript: Q2 2026 - Transcripts
- 2 months ago - SAB Biotherapeutics Earnings release: Q2 2026 - Filings